锂盐与喹硫平增效治疗难治性抑郁的临床与成本效果:英国实用性、开放标签、平行组、随机对照优效性试验
该试验在英国六家国民健康服务体系信托机构纳入212例对两种以上抗抑郁药应答不足的难治性抑郁成人,随机分配至锂盐或喹硫平增效决策组。结果显示喹硫平组12个月内抑郁症状严重程度总体负担显著低于锂盐组,停药时间无显著差异,喹硫平更具成本效果。
要点
- 喹硫平组抑郁症状严重程度总体负担显著低于锂盐组(组间差异曲线下面积-68.36,95%CI -129.95至-6.76,p=0.0296)。
- 两组至全因治疗停药时间无显著差异。
- 喹硫平较锂盐更具成本效果。
核心结论
- 试验结果提示喹硫平作为难治性抑郁长期管理的一线增效选择,在减轻抑郁症状方面临床效果优于锂盐,且可能更具成本效果。
研究设计与样本
- 实用性、开放标签、平行组、随机对照优效性试验,在英格兰六家国民健康服务体系信托机构开展。
- 纳入年龄≥18岁、符合DSM-5重性抑郁障碍当前发作、筛选时17项汉密尔顿抑郁量表评分≥14分且对两种以上治疗性抗抑郁药试验应答不足的成人。
- 排除双相障碍诊断或当前精神病性症状者,按1:1随机分配至锂盐或喹硫平处方决策,按中心、抑郁严重程度和治疗抵抗分层,采用区组随机化且区组大小随机变化。
- 随机化后按标准诊疗进行处方前安全检查,再启动试验药物。
- 共同主要结局为12个月内每周用抑郁症状快速清单测量的抑郁症状严重程度及至全因治疗停药时间。
主要发现
- 2016年12月5日至2021年7月26日随机分配212例参与者(97例[46%]男性,115例[54%]女性)至喹硫平组(n=107)或锂盐组(n=105)。
- 参与者平均年龄42.4岁(SD 14.0岁),188例(89%)为白人,7例(3%)为混合族裔,9例(4%)为亚裔,4例(2%)为黑人,3例(1%)为其他族裔,1例(1%)族裔未记录。
- 喹硫平组抑郁症状严重程度总体负担显著低于锂盐组(组间差异曲线下面积-68.36[95%CI -129.95至-6.76;p=0.0296])。
- 两组至停药时间无显著差异。
- 喹硫平较锂盐更具成本效果。
关键数值与推荐
- 共同主要结局为12个月内每周用抑郁症状快速清单测量的抑郁症状严重程度及至全因治疗停药时间。
- 经济分析从国民健康服务体系与个人社会服务视角及社会视角比较两种治疗的成本效果。
- 主要分析在意向治疗人群(所有随机分配参与者)中进行。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Lithium and quetiapine are first-line augmentation options for treatment-resistant depression; however, few studies have compared them directly, and none for longer than 8 weeks. We aimed to assess whether quetiapine augmentation therapy is more clinically effective and cost-effective than lithium for patients with treatment-resistant depression over 12 months. METHODS: We did this pragmatic, open-label, parallel-group, randomised controlled superiority trial at six National Health Service trusts in England. Eligible participants were adults (aged ≥18 years) with a current episode of major depressive disorder meeting DSM-5 criteria, with a score of 14 or higher on the 17-item Hamilton Depression Rating Scale at screening who had responded inadequately to two or more therapeutic antidepressant trials. Exclusion criteria included having a diagnosis of bipolar disorder or current psychosis. Participants were randomly assigned (1:1) to the decision to prescribe lithium or quetiapine, stratified by site, depression severity, and treatment resistance, using block randomisation with randomly varying block sizes. After randomisation, pre-prescribing safety checks were undertaken as per standard care before proceeding to trial medication initiation. The coprimary outcomes were depressive symptom severity over 12 months, measured weekly using the Quick Inventory of Depressive Symptomatology, and time to all-cause treatment discontinuation. Economic analyses compared the cost-effectiveness of the two treatments from both an NHS and personal social services perspective, and a societal perspective. Primary analyses were done in the intention-to-treat population, which included all randomly assigned participants. People with lived experience were involved in the trial. The trial is completed and registered with the International Standard Randomised Controlled Trial registry, ISRCTN16387615. FINDINGS: Between Dec 5, 2016, and July 26, 2021, 212 participants (97 [46%] male gender and 115 [54%] female gender) were randomly assigned to the decision to prescribe quetiapine (n=107) or lithium (n=105). The mean age of participants was 42·4 years (SD 14·0 years) and 188 (89%) of 212 participants were White, seven (3%) were of mixed ethnicity, nine (4%) participants were Asian, four (2%) were Black, three (1%) were of Other ethnicity, and ethnicity was not recorded for one (1%) participant. Participants in the quetiapine group had a significantly lower overall burden of depressive symptom severity than participants in the lithium group (area under the between-group differences curve -68·36 [95% CI -129·95 to -6·76; p=0·0296). Time to discontinuation did not significantly differ between the two groups. Quetiapine was more cost-effective than lithium. 32 serious adverse events were recorded in 18 participants, one of which was deemed possibly related to the trial medication in a female participant in the lithium group. The most common serious adverse event was overdose, occurring in three (3%) of 107 participants in the quetiapine group (seven events) and three (3%) of 105 participants in the lithium group (five events). INTERPRETATION: Results of the trial suggest that quetiapine is more clinically effective than lithium as a first-line augmentation option for reducing symptoms of depression in the long-term management of treatment-resistant depression, and is probably more cost-effective than lithium. FUNDING: National Institute for Health and Care Research Health Technology Assessment programme.
引用
- Cleare AJ, Kerr-Gaffney J, Goldsmith K, et al. Clinical and cost-effectiveness of lithium versus quetiapine augmentation for treatment-resistant depression: a pragmatic, open-label, parallel-group, randomised controlled superiority trial in the UK. Lancet Psychiatry. 2025. PMID: 40113355. doi:10.1016/S2215-0366(25)00028-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。